Leawood, Kansas, October 14, 2026. Prolific Machines, a Prevail Venture Capital portfolio company, has announced the initial close of a $50 million Series B2 financing to scale its light-controlled biomanufacturing platform, as reported by FiercePharma.

Story Highlights

  • Prolific Machines unveiled the initial close of a $50 million Series B2 financing, led by Atoms & Bits and Patrick Soon-Shiong’s Nant Capital, bringing the company’s total funding to more than $100 million to date.
  • The company entered a strategic collaboration with Soon-Shiong’s healthcare organization NantWorks to apply its platform across biologic programs within the NantWorks portfolio.
  • Patrick Soon-Shiong, M.D., and James Stewart, founder of Atoms & Bits and Level One Fund, will join the Prolific Machines board.

Prevail Venture Capital today highlighted reporting by FiercePharma that Prolific Machines, Inc., a Prevail portfolio company, has closed the initial tranche of a $50 million Series B2 round. According to the report, the round was led by Atoms & Bits and Nant Capital, the investment vehicle of physician-entrepreneur Patrick Soon-Shiong, M.D., and brings the company’s total funding to more than $100 million.

Prolific Machines applies optogenetics — the use of light to control living cells — to biomanufacturing. Its photomolecular platform uses light to directly and dynamically manipulate gene expression inside living cells, and its modular illuminator fits independently controllable LED “staves” around standard bioreactors of effectively any size or brand. Optogenetics more broadly was recognized as the basis of the 2026 Nobel Prize in Physiology or Medicine.

“Prolific Machines is the most exciting advance I have seen in biopharma manufacturing in decades. Deniz and his team have built the control system that has long been missing from making medicines in living cells. I look forward to NantWorks and its affiliate companies and Prolific working together on multiple fronts.”
Patrick Soon-Shiong, M.D., Founder, NantWorks (as quoted by FiercePharma)

Earlier in 2026, Prolific Machines reported a productivity milestone of 21 g/L in a 15-day intensified fed-batch Chinese hamster ovary (CHO) cell-line run for a monoclonal antibody — well above the industry standard of below 10 g/L. The company says the new capital will fund scale-up of the platform and expand programs across its CDMO network, with additional work on novel biologics, biosimilars, and viral-vector programs, plus early work toward tissue and organ fabrication.

“It’s become very clear to us that people are very frustrated with the existing tools to control cells. We have this problem right now where we have too many people that want better manufacturing tools.”
Deniz Kent, Ph.D., CEO & Co-Founder, Prolific Machines (as quoted by FiercePharma)

Read the full report at FiercePharma.

About Prolific Machines

Prolific Machines is a biomanufacturing company using light and optogenetics to control living cells, with the goal of becoming an infrastructure provider for biological production. Founded in 2020 and based in Emeryville, California, the company is developing a photomolecular platform for protein therapeutics, viral vectors, and beyond. For more information, visit prolific-machines.com.

About Prevail Venture Capital

Prevail Venture Capital is a Leawood, Kansas venture firm investing out of a $60M Fund I across MedTech & Longevity, Defense & Security Tech, Fintech, Deep Tech, AI, and Robotics. Prevail and its affiliated entities employ more than seventy people, with an experienced operating bench supporting portfolio companies across EOS, Culture Index, finance, marketing, and BD.

Media Contact: Regan Smith · Manager of Investor Relations · venture-capital@prevailiws.com · (913) 295-9500

Safe Harbor Statement: Statements attributed to Prolific Machines, NantWorks, Patrick Soon-Shiong, and other third parties, and reported by FiercePharma, reflect the reporting and views of those sources, not Prevail Venture Capital, and may constitute forward-looking statements within the meaning of applicable securities laws. These statements involve known and unknown risks and other factors that may cause actual results to differ materially from those expressed or implied. Neither Prevail Venture Capital nor the company undertakes any obligation to publicly update or revise any forward-looking statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.